DaVita Inc., the nation’s second largest outpatient dialysis operator, got permission from the Federal Trade Commission March 28 to complete its merger with Renal Ventures Management LLC after it divests seven dialysis centers in New Jersey and Texas.
The deal may put DaVita ahead of its main rival in the outpatient dialysis market, Fresenius Medical Care N.A., Mark Neumann, Editor-in-Chief of Nephrology News & Issues told Bloomberg BNA.
Newmann noted that the latest numbers from each company already put DaVita on top, but that with Renal Ventures’ patients, DaVita would get a solid bump. According to industry sources, Fresenius and ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.